The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

A new generative AI model rapidly generates diverse antimicrobial peptide structures for screening against ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline.It ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Can-Fite’s lead drug candidate, Piclidenoson ... who will share insight into the Company’s current development pipeline and upcoming milestones. Strategically positioned with multiple out ...

GSK said this reflected progress in late stage drug development, including several ... They’ve been held back by concern over the pipeline and what is seen as few near-term catalysts, down ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

It added that it expects further growth to be boosted by its strong pipeline of new drugs, with 71 specialty medicines and vaccines now in clinical development. As a result, the company said it is ...